Skip to main content

Table 1 Patients with suspected VAP

From: Impact of prior statin therapy on the outcome of patients with suspected ventilator-associated pneumonia: an observational study

  Overall Statin previous users Statin-naive patients P
(n = 349) (n = 93) (n = 256)
Age (years) 64.0 (17.0-94.0) 68.0 (27.0-90.0) 63.0 (17.0-94.0) <0.01
SAPS II 50.0 (6.0-109.0) 54.0 (18.0-109.0) 49.0 (6.0-99.0)) 0.06
Gender, male (n (%)) 254 (72.8) 80 (86.0) 174 (68.0) <0.01
Hospitalization prior to ICU admission (n (%)) 347 (62.3) 89 (67.9) 258 (60.6) 0.14
Underlying disease(s)
 COPD (n (%)) 99 (17.7) 33 (25.1) 66 (15.5) 0.01
 Chronic renal failure (n (%)) 23 (6.6) 10 (10.9) 13 (5.1) 0.05
 Chronic cardiac disease (n (%)) 138 (39.6) 65 (70.6) 73 (28.5) <0.01
 Diabetes mellitus (n (%)) 67 (19.2) 29 (31.5) 38 (14.8) <0.01
 Cirrhosis (n (%)) 17 (4.9) 2 (2.2) 15 (5.9) 0.16
Immunosuppression (excepting steroids) (n (%)) 17 (4.9) 4 (4.3) 13 (5.1) 0.78
 Steroids (n (%)) 20 (5.8) 8 (8.7) 12 (4.7) 0.16
 Cancer (n (%)) 31 (8.9) 10 (10.9) 21 (8.2) 0.44
Nursing-home resident (n (%)) 16 (4.6) 2 (2.1) 14 (5.5) 0.19
Main admission diagnosis     0.20
 Respiratory distress (n (%)) 133 (38.1) 33 (35.5) 100 (39.1) 0.54
 Extrapulmonary sepsis (n (%)) 107 (30.6) 33 (35.5) 74 (69.2) 0.24
 Neurologic failure (n (%)) 50 (14.3) 10 (10.7) 40 (15.6) 0.24
 Abdominal surgery (n (%)) 17 (4.9) 2 (2.1) 15 (5.8) 0.15
 Miscellaneous (n (%)) 42 (12.0) 15 (16.1) 27 (10.5) 0.16
  1. Baseline characteristics according to statin exposure. VAP, ventilator-associated pneumonia; SAPS II, simplified acute physiology score II; ICU, intensive care unit; COPD, chronic obstructive pulmonary disease; MV, mechanical ventilation.